1. Ursin G, Benstein L, Pike MC. Breast cancer. Cancer
Surv. 1994; 19-20: 21-264.
2. Cotton RE. Disease of the breast. Fourth edition. Black
Well scientific publication. 1993; 51-59.
3. Parkin DM. Cancer in developing countries. Cancer Surv.
1994; 19-20: 519-561.
4. Van Dam PA, Van Goethem MLA, Kersschot E, et al.
Palpable solit breast masses: retrospective single and
multimodality evaluation of 201 lesions. Radiology 1988;
166: 435-439.
5. Nemoto T, Natarajan N, Smart CR. Patterns of breast
cancer detection in the United States. J Surgy Oncol
1982; 21: 183-185.
6. Wolfe JN. Analysis of 462 breast carcinoma. A J R 1974;
121: 846-849.
7. Fletcher SW, Black W, Harris R. Report of the
international workshop on screening for breast cancer. J
Natl Cancer Inst 1993; 85: 1644-1656.
8. Tabar L, Duffy SW, Krusemo UB. Detection method,
tumor size and node metastases in breast cancer
diagnosed during a trial of breast cancer screening. Eur J
Cancer Clin Oncol 1987; 23: 959-962.
9. Sickles EA. Breast masses: Mammographic evaluation.
Radiology 1989; 173: 297-303.
10. Kopans DB, Feig SA. False positive rate of screening
mammography. N Eng J Med 1998; 339: 562-564.
11. Kopans DB. The positive predictive value of
mammography. Am J Roentgenol 1992; 158: 521-526.
12. Bird RE, Wallace TW, Yankaskas BC. Analysis of
cancer missed at screening mammography. Radiology
1992; 184: 613-617.
13. Mann BD, Giuliano AE, Bassett LW, et al.Dilayed
diagnosis of breast cancer as a result of normal
mammograms. Arch Surg 1983; 118: 23-25.
14. Kopans DB, Meyer JE, Lindfold KK. Whole breast
ultrasound imaging: four year follow up. Radiology 1985;
157: 505-507.
15. Griffith CN, Kern WH, Mikkelsen WP. Needle aspiration
cytologic examination in the managment of suspicious
lesions of the breast. Surg Gynecol Obstet 1986; 162:
142-144.
16. Kagali VA. The role and limitations of frozen section
diagnosis of a palpable mass in the breast. Surg Gynecol
Obstet 1983; 156: 168-162.
17. Layfield LJ, Glasgow BJ, Gramer H. Fine needle
aspiration in the management of breast masses. Path Ann
1989; 24: 23-62.
18. Cancroft ET, Goldsmith SJ. Technetium-99mpertechnetate
scintigraphy as an aid in the diagnosis of
the breast masses. Radiology 1973; 106: 441-444.
19. Waxman AD, Ramanna L, Memsic LD, et al. Thallium
scintigraphy in the evaluation of mass abnormalities of
breast. J Nucl Med 1993; 34: 18-23.
20. Aktolun C, Bayhan H, Kır M. Clinical experience with
Tc99m-MIBI imaging in patients with malignant tumor;
preliminary results and comparison with Tl201. Clin Nucl
Med 1992; 17: 171-176.
21. Jackson VP, Hendric RE, Kerg SA, et al. Imaging of the
radiographically dense breast. Radiology 1993; 198: 297-
301.
22. Garty I, Friedman A, Sandler MP, Kedar A.
Neuroblastoma : imaging evaluation by sequential Tc99m
MDP, I-131-MIBG and Ga-67-citrate studies. Clin Nucl
Med 1989; 14: 515-522.
23. Piccolo S, Lastoria S, Mainolfi C, et al. Technetium 99m
methylene difosphanate scintimamography to image
primary breast cancer. J Nucl Med 1995; 36: 718-24.
24. Piccolo S, Lastoria S. Scintimamography with 99m Tc
MDP in the detection of primary breast cancer. Q J Nucl
Med 1997; 41: 225-230.
25. Lebowitz E, Greene MW, Greene R, et al. Thallium-201
for medical use. J Nucl Med 1975; 16: 151-155.
26. Belfer AJ, Cox PH, Van WB. Thallium 201 chloride
uptake in tumors, a possible complication in heart
scintigraphy. Br J Radiol 1976; 49: 767-771.
27. Ando A, Ando I, Katayama M, et al. Biodistribution of
Tl-201 in tumor bearing animals and inflammatory lesion
induced animals. Eur J Nucl Med 1987; 12: 567-572.
28. Senga O, Hanamura N, Teari N, et al. Clinical evaluation
of the Tl-201 chloride scintigraphy for breast tumors.
Kaku Igaku 1985; 22: 1021-1028.
29. Badfelt PA, Cancroft ET, Atkins HL, et al. Usefulness of
Tl-201 scintigraphy in breast cancer diagnosis. Radiology
1994; 300: 193P.
30. Edward CL, Hayes RL. Tumor scanning with 67 gallium
citrate. J Nucl Med 1969; 10: 103-105.
31. Hayes RL, Rafter JJ, BYRD BL. Studies of the in vivo
entry of gallium 67 into normal and malignant tissue. J
Nucl Med 1981; 22: 325-332.
32. Hoffer PB, Huberty J, Kyaham-Bashi J. The associated of
gallium 67 and lactoferrin. J Nucl Med 1977; 18 :713-
717.
33. Weiner RE, Schrieber GJ, Hoffer PB. In-vitro transfer of
gallium 67 from transferrin to ferritin. J Nucl Med 1983;
24: 608-614.
Ekim-Aralık 2003 NÜKLEER TIP; ERDOĞAN
225
34. Kim YC, Brown ML, Thrall JH. Scintigraphic patterns of
Ga-67 uptake in the breast. Radiology 1977; 124: 169-
172.
35. Clarke SEM. Tumor imaging. Clinical Nuclear Medicine.
Ed. Maisey MM, Britton KE, Gilday DL. Second edition.
London, Chapman-Hall Medical,1992; 426-459.
36. Kwekkeboom DJ, Krenning EP. Somatostatin receptor
imaging. Semin Nucl Med 2002; 32: 84-91.
37. Van Eijck CHJ, Krenning EP, Bootsma A, et al.
Somatostatin-receptors scintigraphy in primary breast
cancer. Lancet 1994; 343: 640-643.
38. Chiti A, Agresti R, Maffioli LS, et al. Breast cancer
staging using technetium-99m sestamibi and indium-111
pentetreotide single-photon emission tomography. Eur J
Nucl Med 1997; 24: 192-196.
39. Marzullo P, Sambuceti G, Parodi O. The role of sestamibi
scintigraphy in the radioisotopic assessment of
myocardial viability. J Nucl Med 1992; 33: 1925-1930.
40. Hassan IM, Sehweil A, Constantinides C, et al. Uptake
and kinetics of Tc9-9m hexakis 2-methoxy isobutyl
isonitrile in benign and malignant lesions in the lungs.
Clin Nucl Med 1989; 14: 333-340.
41. Palmedo H, Biersack HJ, Lastoria S, et al.
Scintimammography with technetium-99m
methoxyisobutylisonitrile: results of a prospective
European multicentre trial. Eur J Nucl Med 1998; 25:
375-385.
42. Khalkhali I, Cutrone J, Mena I, et al. The usefulness of
scintimammography in patients with dense breasts on
mammogram. J Nucl Med 1995; 36: 52P.
43. Taillefer R, Robidoux A, Lambert R, et al. Tc99m
sestamibi prone scintimammography to detect primary
breast cancer and axillary lymph node involvement. J
Nucl Med 1995; 36: 1758-1765.
44. Mekhmandarow S, Sandbank J, Cohen M, et al.
Technetium-99m-MIBI scintimammography in palpable
and nonpalpable breast lesions. J Nucl Med 1998; 39: 86-
91.
45. Lumachi F, Marzola MC, Zacchetta P, et al. Breast
cancer detection with 99m-Tc-sestamibi scintigraphy,
mammography, and fine-needle aspiration cytology:
comparative study in 64 surgically treated patients. Ann
Surg Oncol 1999; 6: 568-571.
46. Burak Z, Argon M, Memiş A, et al. Evaluation of
palpable masses with Tc99m MIBI: a comparative study
with mammography and ultrasonography. Nucl Med
Comm 1994; 15: 604-612.
47. Rigo P, Paulus P, Kaschten BJ, et al. Oncological
applications of positron emission tomography with
fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996;
23: 1641-1674.
48. Weber WA, Avril N, Schwaiger M. Relevance of
positron emission tomography (PET) in oncology.
Strahlenther Onkol 1999; 175: 356-373.
49. Som P, Atkins HL, Bandoypadhay D, et al. A fluorinated
glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18):
Nontoxic tracer for rapid tumor detection. J Nucl Med
1980; 21: 670-675.
50. Warburg O, Wind F, Neglers E. The metabolism of
tumors. London, Arnold Constable, 1930; 254-270.
51. Warburg O. On the origon of cancer cells. Science 1956;
123: 309-321.
52. Avril N, Schelling M, Dose J, et al. Utility of PET in
breast cancer. Clin Pos Imag 1999; 2: 261-271.
53. Avril N, Dose J, Janicke F, et al. Assessment of axillary
lymph node involvement in the breast cancer patients
with positron emission tomography using radiolabeled 2-
(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl Cancer
Inst 1996; 88: 1204-1209.
54. Moon DH, Maddahi J, Silverman DH, et al. Accuracy of
whole body fluorine-18-FDG PET for the detection of
recurrent or metastatic breast carcinoma. J Nucl Med
1998; 39: 431-435.
55. Wahl RL, Zasadyn K, Helvie M, et al. Metabolic
monitoring of breast cancer chemohormonotherapy using
positron emission tomography: initial evaluation. J Clin
Oncol 1993; 11: 2101-2111.
56. Jansson T, Westlin JE, Ahlstrom H, et al. Positron
emission tomography studies in patients with locally
advanced and/or metastatic breast cancer: A method for
early therapy evaluation? J Clin Oncol 1995; 13: 1470-
1477.
57. Bassa P, Kim EE, Inoue T, et al. Evaluation of
preoperative chemotherapy using PET with fluorine-18-
fluorodeoxyglucose in breast cancer. J Nucl Med 1996;
37: 931-938.
58. Schelling M, Avril N, Nahrig J, et al. Positron emission
tomography using F-18 fluorodeoxyglucose for
monitoring primary chemotherapy in breast cancer. J Clin
Oncol 2000; 18: 1689-1695.
59. Scheidhauer K, Scharl A, Pietrzyk U, et al. Qualitative F-
18 FDG positron emission tomography in primary breast
cancer: Clinical relevance and practicability. Eur J Nucl
Med 1996; 23: 618-623.
60. Tahara T, Ichiya Y, Kuwabara Y, et al. High [18-F]-
fluorodeoxyglucose uptake in abdominal abcesses: A
PET study. J Comput Assist Tomogr 1989; 13: 829-831.
61. Lewis P, Salama A. Uptake of fluorine-18-
fluorodeoxyglucose in sarcoidosis. J Nuc Med 1994; 35:
1647-1649.
62. Avril N, Rose CA, Schelling M, et al. Breast imaging
with positron emission tomography and fluorine-18-
fluorodeoxyglucose: Use and limitaitons. J Clin Oncol
2000; 18: 3495-3502.
